VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2020 | Venetoclax plus low-dose cytarabine in untreated older AML patients

Andrew Wei, MBBS, PhD, of Alfred Hospital and Monash University, Melbourne, Australia, updates us on the Phase III study of venetoclax plus low-dose cytarabine in previously untreated older patients with acute myeloid leukemia (AML). Dr Wei further details an updated analysis of the phase Ib study with 3.5 years median follow-up also in untreated, older AML patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter